11:14 AM EDT, 06/05/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Wednesday it completed the dosing of nine participants in the second group of its human pilot study evaluating semaglutide formulations.

The company said it expects to complete the third round of the study in early July.

The study compares swallowed tablet, capsule and in-mouth dissolvable oral tablet of 7-milligram semaglutide to measure tolerability, side effects, as well as semaglutide and glucose levels in the blood, the company said.

Price: 3.99, Change: -0.02, Percent Change: -0.38